Thursday, September 15, 2016 7:54:10 AM
Thu September 15, 2016 7:00 AM|PR Newswire | About: SNGX
PRINCETON, N.J., Sept. 15, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix (SNGX) or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, has been invited to present a company overview at the 2016 Aegis Growth Conference on Wednesday, September 21, 2016 at 9:30 a.m. PDT in Room 4. The conference will be held at the Encore at Wynn Las Vegas in Las Vegas, Nevada. For more information on the conference, please go to www.aegiscapcorp.com.
Recent SNGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:05:27 PM
- Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting • PR Newswire (US) • 05/24/2024 11:30:00 AM
- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split • PR Newswire (US) • 05/23/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/22/2024 08:05:06 PM
- PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon • GlobeNewswire Inc. • 05/21/2024 04:35:16 PM
- SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference • PR Newswire (US) • 05/21/2024 11:30:00 AM
- Soligenix Encourages Stockholders to Vote Prior to Annual Meeting • PR Newswire (US) • 05/20/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:25:40 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/17/2024 08:09:20 PM
- Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2024 08:05:38 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:16:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:05:50 PM
- Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results • PR Newswire (US) • 05/10/2024 11:30:00 AM
- Soligenix to Present at Upcoming Conferences • PR Newswire (US) • 05/06/2024 11:30:00 AM
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa • PR Newswire (US) • 04/25/2024 11:30:00 AM
- Soligenix Announces Pricing of $4.75 Million Public Offering • PR Newswire (US) • 04/18/2024 12:30:00 PM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection • PR Newswire (US) • 04/15/2024 11:30:00 AM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection • PR Newswire (US) • 04/11/2024 11:30:00 AM
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency • PR Newswire (US) • 04/03/2024 11:30:00 AM
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results • PR Newswire (US) • 03/15/2024 11:30:00 AM
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board • PR Newswire (US) • 02/08/2024 12:30:00 PM
- Soligenix to Present at The Microcap Conference • PR Newswire (US) • 01/25/2024 12:30:00 PM
- FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis • PR Newswire (US) • 01/04/2024 12:30:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM